Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	51.62	99.11	35.23	256.74	347.12	152.82
Cash & Cash Equivalents	51.62	99.11	35.23	256.74	347.12	152.82
Cash Growth	-65.83%	181.34%	-86.28%	-26.04%	127.14%	-30.15%
Receivables	670.48	614.69	742.29	663.76	640.3	606.16
Inventory	570.65	581.38	530.74	489.39	490.65	381.07
Other Current Assets	87.3	82.69	103.57	110.22	73.47	70.16
Total Current Assets	1,380	1,378	1,412	1,520	1,552	1,210
Property, Plant & Equipment	544.79	550.14	589.36	639	604.71	609.15
Goodwill and Intangibles	1,458	1,489	1,695	1,760	1,827	1,802
Other Long-Term Assets	73.75	55.52	103.22	20.61	22.34	44.27
Total Long-Term Assets	2,076	2,095	2,388	2,420	2,454	2,456
Total Assets	3,456	3,473	3,799	3,940	4,006	3,666
Accounts Payable	569.91	546.44	547.85	534.96	613.45	507.48
Current Debt	228.67	227.62	104.64	46.04	57.47	36.95
Other Current Liabilities	35.81	72.53	100.31	96.24	5.98	5.97
Total Current Liabilities	834.39	846.6	752.8	677.24	676.9	550.41
Long-Term Debt	2,517	2,523	2,740	2,830	2,887	2,729
Other Long-Term Liabilities	168.47	83.06	122.07	65.43	96.75	39.58
Total Long-Term Liabilities	2,686	2,606	2,863	2,895	2,984	2,769
Total Liabilities	3,520	3,453	3,615	3,573	3,661	3,319
Total Debt	2,746	2,751	2,845	2,876	2,945	2,766
Debt Growth	-3.77%	-3.33%	-1.08%	-2.34%	6.47%	2.77%
Retained Earnings	-581.82	-490.18	-406.18	-276.2	-286.82	-377.88
Comprehensive Income	-23.71	-32.35	9.94	-24.83	-41.32	-0.07
Shareholders' Equity	-63.72	19.78	298.42	360.34	303.27	232.01
Net Cash / Debt	-2,694.21	-2,651.42	-2,809.91	-2,619.32	-2,597.8	-2,613.25
Net Cash Per Share	-8.77	-15.05	-18.62	-17.25	-17.45	-19.78
Working Capital	545.66	531.27	659.02	842.87	874.64	659.8
Book Value Per Share	-0.21	0.11	1.98	2.42	2.06	1.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).